Nomad Bioscience

inspired by nature and evolution

Antibacterial Biologics

The Threat

of failing bacterial disease control

Antibiotics, the most effective medicine of the XXth century, are failing because of the rampant rise of bacterial resistance, with multi-drug and pan-drug resistant pathogens becoming a common case
We are in the middle of another, silent bacterial, pandemic, and if nothing is done, by 2050, we'll return to 'pre-penicillin era', with 700 thousand Europeans dying yearly from bacterial superbugs

Broad antimicrobial activity of antibiotics and their 'carpet bombing' effect comes with a high price of destroying our gut microbiome, resulting in new diseases, and it causes incompatibility with other modern medicines such as anti-cancer drugs



NOMAD

Imagine

that we could replace non-specifically acting, and rapidly failing, antibiotics with high precision antibacterial biologics with a novel mode of action

- Transformative biologics' therapies for multiple diseases well beyond just a bacterial control
- Focused first-in-human trials in defined patient populations
- Opportunity to build a sustainable, high value biotech company

NOMAD

Bacteriocins

precision antibacterial biologics invented by nature

Evolved naturally by bacteria to fight same or similar bacterial species

- Highly potent *in vitro* and *in vivo*, rapid acting, multiple modes of action, huge natural diversity, easy to engineer, easy to produce and purify
- Due to novel modes of action, excellent control of multi-/pan-drug resistant bacteria
- Destroy only the pathogenic species while sparing gut microbiome

NOMAD

Bacteriocins

precision antibacterial biologics invented by nature





NOMAD

Strategy

a match between technology and value creation

- Focus on the most difficult to treat Gram-negative pathogens (*Klebsiella, Pseudomonas, Escherichia,* etc.), filing patents aiming at a broad exclusivity
- First candidates aim at highly lucrative blood infection (bacteraemia) control market
- Addressing combination therapies, beyond simple antibiotic replacement, with much more attractive pricing
- A pipeline of carefully selected candidates for large strategic markets as well as opportunistic products for niche markets with fast, low-cost market entry



NOMAD

Achievements

With €14 million invested since 2014

- Mined/engineered large libraries of natural and engineered bacteriocins
- Multiple tier selection identified several lead molecules currently in preclinical testing
- Candidates show high efficacy in multiple validated animal models; GLP toxicology for main candidates to be completed by mid-2022
- Broad patents filed (in part granted) that will assure Nomad's exclusivity



NOMAD

Recent Progress, Important Value Inflection Points Ahead

- NOMAD has identified six product candidates for preclinical development and plans to complete preclinical studies for two of them by mid-2022
- High efficacy of bacteriocin candidates confirmed for various indications including **bacteraemia (primary - focus), intestinal tract infection**, **lung infection, and eye infection**
- IND enabling (toxicology) studies are ongoing
- CMOs selected for GMP-certified bacteriocin products, necessary for Phase I and II clinical trials
- Ongoing dialogue with clinicians, key opinion leaders and CROs in designing the clinical trials as well as identifying potential participating hospitals and CROs

NOMAD

Next

From start-up to clinical stage company

- Cement foothold as the dominant developer of antibacterial biologics for multiple applications
- Progress quickly with at least two candidates to *first-in-human clinical trials*, complete Phase II for at least two candidates
- First-in-man clinical trials expected by 2022
- Further build-out our team, especially including medical development & clinical expertise
- Expand business development/deal making for synergy/acceleration

NOMAD

NOMAD‘s Pipeline by Q4 2024

Continued mining for product candidates will yield a risk-hedged program portfolio, including clinical stage candidates

Candidate	Disease	Target	Stage, Q4 24
NMD01	Bacteraemia	multidrug resistant *Klebsiella/Escherichia*	Phase II complete
NMD02	Cancer	multidrug resistant *Klebsiella/Escherichia*	IND/Phase I complete*
NMD03	Lung infection	multidrug resistant *Pseudomonas*	IND/Phase I complete*
NMD04	Eye infection	multidrug resistant *Pseudomonas*	Phase II complete

* Phase I complete subject to additional non-dilutive financing

NOMAD to become a clinical stage company in Q4 2022!

NOMAD

Summary

NOMAD is a pioneering discoverer and developer of precision antibacterial biologics for treatment of multidrug resistant Gram-negative bacteria

State of the art platforms with IP on antibacterial precision biologics

Strong team, board and scientific advisors



Risk-hedged pipeline of product candidates

Opportunity for IPO or trade sale as leading clinical stage company